Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of AG-519 in healthy volunteers
NCT02630927Phase 1Terminated
- Sponsor
- Agios Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AG-519 in pyruvate kinase deficiency (PKD) (5 arms), sponsored by Agios Pharmaceuticals. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 14 days. Started Dec 2015; status: terminated.
02
Drugs
AG-519
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NCT02630927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630927.